-
Close on the heels of the first positive findings reported in microbicides and vaccine research ventures, the iPrEx study has shown that a pre-exposure prophylaxis (PrEP) combination drug demonstrates 44% additional protection from HIV infection.
-
As institutions continue to weather the economic downturn, the toll on IRB offices is showing. The trends of previous years fewer raises, more job cuts, increasing workloads continued in 2010, according to responses to IRB Advisor's annual Salary Survey.
-
Recruiting patients for Phase I oncology studies which are unlikely to provide therapeutic benefit to participants and which carry the risk of significant side effects raises unique issues in informed consent.
-
As more sophisticated imaging technologies are used in research, investigators and IRBs must grapple with an unintended side effect an increase in incidental findings (IF), or new health data unrelated to the study that is revealed about participants.
-
Researchers might find it tempting to collect data for socio-behavioral studies from social websites like Facebook. Their appeal is having fairly easy access and viewing a broad range of behavioral information.
-
An IRB looking to recruit a good non-scientist to the board may have to look no further than its own institution's medical library.
-
-
IRBs dealing with international or high-risk research can find some guidance on how to handle all stakeholders in studies in the recently-revised Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials (GPP).
-
IRBs at academic research centers often review international infectious diseases research that can raise red flags regarding privacy, confidentiality, and vulnerability.
-
Researchers often criticize IRBs and see them as barriers to research.